Dear valued stakeholders,

I would like to extend my deepest gratitude for your consistent trust and support for SK bioscience.

Guided by our corporate mission—“We promote human health, from prevention to cure”—we are steadfast in our commitment to enhancing global public health. ESG, as a core pillar of our management philosophy to realize this mission, serves as the foundation for sustainable growth through the vision of “Healthier Life, Sustainable Future.”

Over the past year, SK bioscience has incorporated ESG principles into the corporate culture and promoted them across stakeholders. As a result, we achieved meaningful milestones, including receiving A ratings from KCGS for three consecutive years and A ratings from MSCI for two consecutive years. These achievements were supported by our efforts to build globally-aligned systems across the Environmental (E), Social (S), and Governance (G) pillars.

On the environmental front, we marked a significant turning point toward fulfilling our RE100 commitment by signing a Power Purchase Agreement (PPA) for renewable energy. We also proactively prepared for the upcoming mandatory climate-related disclosures by participating for the first time in the global initiative CDP (Carbon Disclosure Project) for climate change. This enabled us to assess our environmental performance in line with international standards and to enhance our readiness for climate-related regulations and policies.

On the social front, we have expanded the scope of our human rights impact assessment to include our business partners and local communities and took proactive steps to mitigate risks by conducting ESG risk assessments and offering consulting support to high-risk partners. In addition, we enhanced ESG capacity-building by running educational programs for our partners.

On the governance front, we reinforced ESG management systems to enable a transparent and accountable decision-making by operating the ESG Committee and establishing a risk management framework centered on the Board of Directors. We also expanded internal communications to raise awareness and foster participation among employees, achieving significant progress in embedding ESG.

In 2025, we aim to deeply embed ESG principles into our organization, integrating sustainability into our core business strategies and corporate culture. We will enhance vaccine accessibility through market expansion and global partnerships, thereby fulfilling our mission to improve public health. Additionally, we will upgrade our Net Zero roadmap in line with our expanding business operations and strengthen employee environmental education.

Following our 2023 efforts, we will once again conduct a comprehensive human rights impact assessment, focusing on workplace ethics, diversity, and inclusion (DE&I). Through corporate philanthropic activities and team-based workshops, we will promote the integration of ESG into employees’ daily routines and work, embedding it into our corporate culture.

SK bioscience believes that ESG is not just a responsibility, but a driver of long-term value creation. We will continue our efforts for a sustainable future and grow as a company that contributes to humanity and society.

We request your continued interest and support on our journey for the sustainable future. Thank you.

Jaeyong AhnPresident and Chief Executive Officer